Future cases would benefit from comprehensive molecular testing, including NGS panels for GNAQ/GNA11, BRAF/NRAS, TERT promoter and tumor suppressor genes (e.g., BAP1), as well as immunohistochemistry for p16 and PRAME, to better delineate the tumor’s origin and to guide prognosis and targeted therapy [14]. This evidence concerns the gene NRAS and neoplasm.